Larimar Therapeutics (LRMR) Equity Average: 2014-2020
Historic Equity Average for Larimar Therapeutics (LRMR) over the last 6 years, with Sep 2020 value amounting to $107.6 million.
- Larimar Therapeutics' Equity Average rose 63.00% to $107.6 million in Q3 2020 from the same period last year, while for Sep 2020 it was $107.6 million, marking a year-over-year increase of 63.00%. This contributed to the annual value of $46.3 million for FY2019, which is 46.02% down from last year.
- Larimar Therapeutics' Equity Average amounted to $107.6 million in Q3 2020, which was up 31.78% from $81.6 million recorded in Q2 2020.
- Larimar Therapeutics' Equity Average's 5-year high stood at $161.8 million during Q1 2016, with a 5-year trough of $25.0 million in Q1 2020.
- Its 3-year average for Equity Average is $71.1 million, with a median of $77.3 million in 2019.
- Data for Larimar Therapeutics' Equity Average shows a peak YoY increase of 63.00% (in 2020) and a maximum YoY decrease of 71.50% (in 2020) over the last 5 years.
- Quarterly analysis of 5 years shows Larimar Therapeutics' Equity Average stood at $126.0 million in 2016, then tumbled by 33.53% to $83.7 million in 2017, then rose by 17.77% to $98.6 million in 2018, then plummeted by 69.99% to $29.6 million in 2019, then soared by 63.00% to $107.6 million in 2020.
- Its last three reported values are $107.6 million in Q3 2020, $81.6 million for Q2 2020, and $25.0 million during Q1 2020.